Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions around the publication consistently highlight the drug’s activity in tumors with FGFR mutations or fusions, using words like 'activity' and 'potential' to suggest optimism. The tone varies from optimistic to cautious, with some expressing disappointment about limited efficacy against amplifications, which reflects exploratory and evaluative attitudes typical of academic and clinical discussions.
Most posts recognize the study's findings, particularly the efficacy of erdafitinib in specific genetic contexts, showing general support for the publication’s conclusions.
Discussions reflect high curiosity, especially around the drug’s potential and the implications for broader cancer applications, indicating significant interest.
Posts mention key trial results, highlight the significance, and express some hope or skepticism, demonstrating moderate deep engagement with the research.
While some posts emphasize the importance of the findings and their potential influence on treatment strategies, the overall perception of impact remains cautious and exploratory.
1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in treatment-refractory tumors w/#FGFR1-3 mutations or fusions, adding to evid for potential tumor agnostic indication? https://t.co/uTFn7Tq530 @OncoAlert https://t.co/GLVzd2kzn3
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology @jgong15 https://t.co/a7C4fJ3wtx
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 | JCO Precision Oncology @jgong15 https://t.co/EPel7jNkgP
Ugh, I was really hoping this would be positive. Anyone have ideas on
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology https://t.co/U2lAIPOcvh
DRUG TARGETS: in a pair of NCI-MATCH trials, FGFR inhibition (erdafitinib) was ineffective against cancers with FGFR1-4 amplifications (ORR 0%) but showed some efficacy against cancers with fusions or activating mutations (ORR 16%). https://t.co/y58I6y2FyS https://t.co/QuIcfPDqfJ
Dr Jun Gong discusses the limited activity of Erdafitinib in tumors with FGFR amplifications, mutations, or fusions based on recent phase II trial results. The study shows limited responses, with some stable disease…
DRUG TARGETS: in a pair of NCI-MATCH trials, FGFR inhibition (erdafitinib) was ineffective against cancers with FGFR1-4 amplifications (ORR 0%) but showed some efficacy against cancers with fusions or activating mutations (ORR 16%). https://t.co/y58I6y2FyS https://t.co/QuIcfPDqfJ
Ugh, I was really hoping this would be positive. Anyone have ideas on
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @jgong15: 1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in tr…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
https://t.co/Naa0qke59A
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @DraMartinezLago: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Res…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @jgong15: 1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in tr…
RT @DraMartinezLago: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Res…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology @jgong15 https://t.co/a7C4fJ3wtx
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 | JCO Precision Oncology @jgong15 https://t.co/EPel7jNkgP
RT @jgong15: 1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in tr…
RT @jgong15: 1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in tr…
RT @DraMartinezLago: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Res…
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology https://t.co/U2lAIPOcvh
RT @jgong15: 1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in tr…
RT @jgong15: 1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in tr…
1/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in treatment-refractory tumors w/#FGFR1-3 mutations or fusions, adding to evid for potential tumor agnostic indication? https://t.co/uTFn7Tq530 @OncoAlert https://t.co/GLVzd2kzn3